Candriam SCA’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-210,027
| Closed | -$256K | – | 693 |
|
|
2024
Q2 | $256K | Buy |
+210,027
| New | +$256K | ﹤0.01% | 672 |
|
|
2022
Q3 | – | Sell |
-1,653,988
| Closed | -$3.03M | – | 875 |
|
|
2022
Q2 | $3.03M | Hold |
1,653,988
| – | – | 0.02% | 412 |
|
|
2022
Q1 | $4.42M | Sell |
1,653,988
-106,934
| -6% | -$286K | 0.03% | 374 |
|
|
2021
Q4 | $7.62M | Sell |
1,760,922
-1,545,018
| -47% | -$6.69M | 0.05% | 298 |
|
|
2021
Q3 | $16.8M | Buy |
3,305,940
+977,587
| +42% | +$4.98M | 0.11% | 199 |
|
|
2021
Q2 | $14.7M | Buy |
2,328,353
+2,328,207
| +1,594,662% | +$14.7M | 0.1% | 232 |
|
|
2021
Q1 | $1K | Buy |
+146
| New | +$1K | ﹤0.01% | 792 |
|
|
2020
Q2 | – | Sell |
-741,191
| Closed | -$6.02M | – | 814 |
|
|
2020
Q1 | $6.02M | Buy |
741,191
+47
| +0% | +$382 | 0.07% | 303 |
|
|
2019
Q4 | $6.16M | Buy |
741,144
+53,311
| +8% | +$443K | 0.07% | 309 |
|
|
2019
Q3 | $5.08M | Hold |
687,833
| – | – | 0.07% | 314 |
|
|
2019
Q2 | $7.68M | Buy |
687,833
+19,000
| +3% | +$212K | 0.1% | 234 |
|
|
2019
Q1 | $7.19M | Buy |
668,833
+177,845
| +36% | +$1.91M | 0.09% | 250 |
|
|
2018
Q4 | $7.41M | Buy |
490,988
+98,261
| +25% | +$1.48M | 0.11% | 210 |
|
|
2018
Q3 | $7.27M | Buy |
392,727
+212,600
| +118% | +$3.93M | 0.1% | 247 |
|
|
2018
Q2 | $4.12M | Buy |
180,127
+139,127
| +339% | +$3.18M | 0.07% | 335 |
|
|
2018
Q1 | $1.17M | Sell |
41,000
-48,000
| -54% | -$1.37M | 0.02% | 568 |
|
|
2017
Q4 | $1.88M | Sell |
89,000
-76,000
| -46% | -$1.6M | 0.03% | 467 |
|
|
2017
Q3 | $3M | Sell |
165,000
-30,000
| -15% | -$545K | 0.05% | 370 |
|
|
2017
Q2 | $3.02M | Hold |
195,000
| – | – | 0.06% | 380 |
|
|
2017
Q1 | $3.37M | Buy |
195,000
+40,000
| +26% | +$691K | 0.07% | 343 |
|
|
2016
Q4 | $1.7M | Hold |
155,000
| – | – | 0.04% | 399 |
|
|
2016
Q3 | $2.43M | Buy |
155,000
+88,000
| +131% | +$1.38M | 0.06% | 318 |
|
|
2016
Q2 | $684K | Buy |
67,000
+25,000
| +60% | +$255K | 0.02% | 508 |
|
|
2016
Q1 | $539K | Buy |
42,000
+32,000
| +320% | +$411K | 0.01% | 536 |
|
|
2015
Q4 | $209K | Buy |
+10,000
| New | +$209K | 0.01% | 537 |
|